Ruxolitinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ruxolitinib and local guidelines before prescribing.
JAK inhibitor
Mechanism
JAK1 and JAK2 inhibitor.
Uses
Myelofibrosis, polycythaemia vera, graft-versus-host disease.
Dosing
- Treatment: Stop the checkpoint inhibitor; IV methylprednisolone 500–1000 mg daily for 3–5 days, then oral steroid taper; second-line agents (e.g. abatacept, mycophenolate, ruxolitinib) for steroid-refractory disease.
Cardiology: Cardiomyopathies
Side effects
Anaemia, thrombocytopenia, infections, bruising, weight gain.
Interactions
CYP3A4 inhibitors raise levels.
Contraindications and cautions
Active serious infection
Monitoring
FBC, LFT
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Dose by platelets and renal function
Overdose and reversal
Supportive
Special advice
Do not stop abruptly; FBC monitoring.
More from the textbook: uses, cautions and other points
- Polycythaemia vera - to keep haematocrit under 0.45 ; plus low-dose aspirin ; hydroxycarbamide or interferon (pregnancy) for high-risk patients; ruxolitinib (JAK inhibitor) if resistant.
Haematology: Anatomy Physiology and Pharmacology - Ruxolitinib (JAK1/2) | Myelofibrosis, polycythaemia vera, graft-versus-host disease | Anaemia, low platelets, infections (shingles, TB), skin cancer
Haematology: Anatomy Physiology and Pharmacology - Ruxolitinib if resistant or intolerant.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - JAK inhibitors - ruxolitinib (reduces spleen and symptoms; worsens anaemia and low platelets; infections such as shingles), fedratinib , momelotinib (helps anaemia), pacritinib (low platelets).
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Acute graft-versus-host disease (usually in the first 100 days) - skin rash (palms and soles), diarrhoea , jaundice . Treated with steroids, ruxolitinib.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Ruxolitinib | Myelofibrosis, PV (resistant), GvHD; anaemia, low platelets, shingles.
Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia - Treatment - urgent haematology and immunology input; treat the trigger; dexamethasone and etoposide (HLH-94 protocol); anakinra (especially MAS), ciclosporin, emapalumab (anti-IFN-γ), ruxolitinib; stem cell transplant for primary or refractory HLH.
Clinical Immunology: Primary immunodeficiency - Treatment - corticosteroids (topical for mild skin, systemic for more); steroid-refractory - ruxolitinib (JAK inhibitor), belumosudil (chronic), extracorporeal photopheresis.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Cardiology: Cardiomyopathies (1 mention)
- Haematology: Anatomy Physiology and Pharmacology (2 mentions)
- Haematology: Leukaemias, myeloproliferative neoplasms and myelodysplasia (4 mentions)
- Clinical Immunology: Primary immunodeficiency (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated cardiology chapter (1 mention)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)